CytomX Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

CTMX$1.980.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

CONDENSED STATEMENTS OF OPERA TIONS AND COMPREHENSIVE INCOME (LOSS)

(in thousands, except share and per share data)

Three Months Ended · Six Months Ended
	June 30,		June 30,
	2024	2023	2024	2023
Revenues	$25,115	$24,724	$66,578	$48,223
Operating expenses:
Research and development	25,172	20,671	47,224	41,846
General and administrative	8,395	7,401	16,149	15,378
Total operating expenses	33,567	28,072	63,373	57,224
Income (Loss) from operations	(8,452)	(3,348)	3,205	(9,001)
Interest income	1,971	2,308	4,165	4,635
Other (expense) income, net	(2)	(47)	(12)	(32)
Income (Loss) before income taxes	(6,483)	(1,087)	7,358	(4,398)
Provision for income taxes	51	—	101	—
Net Income (loss)	(6,534)	(1,087)	7,257	(4,398)
Other comprehensive income (loss):
Unrealized (loss) gain on investments, net of tax	6	9	(99)	25
Total comprehensive income (loss)	$(6,528)	$(1,078)	$7,158	$(4,373)
Net income (loss) per share:
Basic	$(0.08)	$(0.02)	$0.09	$(0.07)
Diluted	$(0.08)	$(0.02)	$0.09	$(0.07)
Shares used to compute net income (loss) per share
Basic	84,880,632	66,536,202	83,455,047	66,393,391
Diluted	84,880,632	66,536,202	84,115,530	66,393,391

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.